CHRONVAC-C Study Followed by Standard of Care in Chronic Hepatitis C Virus (HCV) Subjects

Inclusion Criteria: * Male or female subject 18 - 65 years of age with a known chronic hepatitis C infection, being treatment naїve (that is not being earlier treated for HCV infection) and a planned start of standard of care within 12 weeks from screening. * Known genotype 1 infection. * Viral load equal to 1000 IU/ml or more * BMI less than 35. * Considered probable that the deltoid muscles (left and right) of the subject will be reached at vaccination using a 12.7 mm cannula for injection and a 15 mm applicator tip for electroporation. * Written informed consent obtained, and a copy provided to the subject. * Subject legally competent and able to communicate effectively with the study personnel. * Subject likely to co-operate and attend the clinic at the appointed times during the study Exclusion Criteria: * Subject having clinically significant concomitant diseases other than HCV in the medical history to the discretion of the investigator. * Subject having clinically significant findings on physical examination, vital signs, ECG or clinical laboratory evaluations to the discretion of the investigator. * Subject having clinical or biochemical signs of cirrhosis. * Positive hepatitis B surface antigen (HBsAg). * Positive HIV antigen or antibody test. * Subject having an ongoing and/or known viral infection other than HCV that requires treatment and/or special medical intention. * Subject having received previous treatment for HCV. * Radiation therapy or cytotoxic chemotherapeutic agents within 4 weeks prior to the first dose of study drug. * Treatment with immunomodulating agents such as systemic corticosteroids, IL-2, IFN-alpha, IFN-beta, IFN-gamma within 4 weeks prior to the first dose of study drug. (Corticosteroid nasal sprays, inhaled steroids for asthma and/or topical steroids are allowed, however not on the vaccination area.) * Immunization within 30 days of the first dose of the study drug. * Subject having received an investigational drug product, or been enrolled in other investigational drug protocols within a period of 30 days prior to receiving the first dose of the study drug. * Prior treatment with DNA therapy. * Known allergy towards vaccines. * Known allergy or contraindications to interferon and/or ribavirin or their excipients * Known abuse of alcohol, drugs or pharmaceuticals. * History, signs or symptoms of a cardiac disease. * Presence of an implantable pacemaker. * Any metal implants within the treatment areas (close to the right and/or left deltoid muscles). * Diagnoses of a serious psychiatric illness which may influence study participation. * Female subject who is pregnant or breast feeding. * Female subject not clinically sterile (hysterectomy, tubal ligation or postmenopausal (amenorrhea \> 1 year and FSH \> 30 mU/ml) OR if not clinically sterile unwilling to use a reliable contraception method. * Female subject with a positive urine pregnancy test. * Male subject unwilling to use condom for active prevention of pregnancy from first vaccination to 4 months after last injection. * Subject or their immediate families being an investigator or site personnel directly affiliated with this study. Immediate family is defined as a spouse, parent, child or sibling, whether biologically or legally adopted.